91 results about "Neurogenesis" patented technology

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.

Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.

A system and method for adaptive neural network architecture with real-time neurogenesis capabilities during inference operations. The system processes data through a core neural network with integrated supervisory and neurogenesis control systems. A hierarchical supervisory network, comprising low-level, mid-level, and high-level nodes, monitors network activity patterns and information flow. The neurogenesis control system maintains continuous activity maps, detects processing bottlenecks, and determines optimal placement of new neurons using geometric optimization. A modification subsystem implements controlled neurogenesis operations while maintaining network stability. The system handles data through adaptive codeword allocation and fusion of dissimilar data types. This sophisticated approach enables neural networks to dynamically expand their processing capacity during operation, responding to detected bottlenecks while maintaining operational stability through carefully managed integration of new neurons.

The invention discloses a preparation method of an antler-DCB (at) EVsABPCs bone graft material. The preparation method specifically comprises the following steps: step 1, preparing an Antler-DCB scaffold; step 2, preparing hydrogel containing 10% of HAMA and ABPCs-Evs (2, 2 '-(1, 2, 4-trimethyl-1, 3, 4- Step 3, mixing; step 4, taking Antler-DCB, and immersing the Antler-DCB into the HAMA hydrogel containing the ABPCs-EVs; and step 5, exposing to 405nm ultraviolet light for 30 seconds to obtain the bone graft material. The invention further discloses the antler-DCB (at) EVsABPCs bone graft material. According to the antler-DCB-coated EVsABPCs bone graft material and the preparation method thereof disclosed by the invention, the strong capability of adjusting osteogenesis, angiogenesis, neurogenesis and immune response is obtained, so that a potential therapeutic intervention measure is provided for treating serious bone defects.

Disclosed are in vitro methods for the differentiation of precursor cells into a neural crest cell (NCC) primed to a neurogenic lineage. The methods may include, for example, the steps of activating a Hedgehog signaling pathway (“HH signaling pathway”) in a precursor cell, wherein the precursor cell may be contacted with a neural crest cell induction medium for differentiation of the precursor cell into a neural crest cell. Compositions for carrying out the disclosed methods are also disclosed.

To achieve in vivo repair of severed mammalian nerve tissue, a system can be employed to induce distraction neurogenesis. At least a portion of the system can be anchored at an injury site, such as between distal and proximal nerve ends. The system can be attached to the proximal nerve end and can place the nerve under micro-tension for an extended period of treatment. The system may also deliver medication or treatment to encourage neurogenesis and to reduce pain in the subject receiving treatment. After the course of treatment, the device can be removed from the injury site, and the nerve ends rejoined.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

Compositions, nucleic acid molecules, and methods for inducing retinal regeneration and reprogramming Muller glial cells (MGs) into retinal ganglion cells in a subject are described. The development of retina ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increases the MG neurogenesis capability induced by Ascl1. The combination of Ascl1, Pou4f2, and Islet1 stimulates the MG to produce bipolar cells and RGC-like neurons. Likewise, a transcription factor Onecut1, which is expressed in developing retinal cells but not expressed in MG, induces MG to produce RCG-like cells. Other transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. The MG-derived RGC can exhibit action potential in vivo, and exhibit chromatin characteristics similar to those of developing RGC.

Disclosed in the present invention is a phosphatidylserine and docosahexaenoic acid (DHA) composite, and its application thereof in a functional preparation, belonging to the field of health-care food. By combining two substances in a specific ratio and further applying them to edible functional preparations, brain entry efficiency of unsaturated fatty acids including DHA is improved. The ratio verifies a synergistic interaction mechanism of two active ingredients. Phosphatidylserine promotes enrichment of fatty acids such as the DHA in a brain by enhancing permeability of a blood-brain barrier, promotes neurogenesis, and enhances learning and memory abilities. Moreover, combination of the phosphatidylserine (PS) and the DHA can significantly improve an expression level of neurotrophic factors and protect and repaire a nervous system. (Figl)

The invention provides a traditional Chinese medicine compound composition with a nerve repairing effect, a cell culture medium, a traditional Chinese medicine-neural stem cell exosome compound and application, and belongs to the technical field of biological medicine. Based on the basic theory of traditional Chinese medicine and the combined theory of traditional Chinese medicine and western medicine, the traditional Chinese medicine compound composition is provided and comprises gastrodia elata exosomes, astragalus membranaceus exosomes and resveratrol, the traditional Chinese medicine compound composition is prepared into a cell culture medium, neural stem cells are cultured through the cell culture medium, and the neural stem cells are obtained. Therefore, the traditional Chinese medicine-neural stem cell exosome compound with an efficient nerve repairing function is prepared. The traditional Chinese medicine-neural stem cell exosome compound achieves the purpose of comprehensively repairing nerve injury by precisely targeting nerve cells, promoting neurogenesis, repairing the function of a neural circuit and reducing the inflammatory effect, and can be used for preparing related medical instruments and drugs for nerve repair.

Novel populations of canine derived stem cells useful for treatment across allogeneic barriers. The stem cells can be of mesenchymal lineage optimized to possess enhanced proliferative activity in vitro and in vivo without significant loss of therapeutic functionality. Said therapeutic activities include angiogenesis, stimulation of growth factor production, antifibrotic effects, neurogenesis, immune modulation, and antiapoptotic effects.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

Provided is a technology capable of promoting neurogenesis. This neurogenesis promoter contains at least one of a substance that inhibits the glutaminolysis pathway and a substance that inhibits mTOR, and is used between postnatal day 0 and corrected age of 20 months of a premature infant.

The invention discloses application of human dental pulp stem cells in enhancing neurogenesis in a brain region and treating neurodegenerative diseases, including stem cells for enhancing neurogenesis of adult hippocampus, and the human dental pulp stem cells have the following functional characteristics: flow cytometry detection shows that the Netin positive rate is not lower than 90%, and the beta-tubulin III positive rate is not lower than 85%; in a conditioned culture medium after in-vitro culture for 24 hours, the secretion amount of BDNF reaches more than 500pg / mL / 106 cells, and the secretion amount of GDNF reaches more than 200pg / mL / 106 cells; the alizarin red dyeing positive area accounts for not less than 60% after osteogenesis induction, and the oil red O dyeing positive area accounts for not less than 50% after adipogenesis induction; according to the quantitative standard that the number of dentate gyrus DCX + newborn neurons of the adult hippocampus is increased by more than 50% compared with that before treatment, the dual-mechanism targeted therapy 1 specifically activates hippocampus neural stem cells and promotes newborn neurons to differentiate by highly expressing neural markers and secreting neurotrophic factors, so that the neurogenesis of the adult hippocampus is enhanced, and the neurogenesis of the adult hippocampus is enhanced. Meanwhile, A beta deposition and p-Tau phosphorylation are reduced.

The invention discloses a method for synergistically treating Alzheimer's disease through gene-modified human interdental stem cells, and belongs to the field of drug therapy. According to the method, healthy adult dental pulp mesenchymal stem cells (hDPSCs) are extracted, BDNF and NRF2 genes are introduced through lentiviral vectors, the BDNF and NRF2 genes have neurotrophic, antioxidant and anti-inflammatory capacities, and then the hDPSCs are combined with curcumin nanoparticles and injected to the hippocampus of an AD mouse through stereotactic injection. The BDNF can promote nerve regeneration, the NRF2 can improve oxidative stress and inflammation environment, and the curcumin nanoparticles regulate A beta metabolism and activate a BDNF signal channel. Experiments show that the combined therapy can significantly enhance hippocampal neurogenesis of AD mice and improve expression of neuron markers, and it is proved through Morse water maze tests that the combined therapy can improve the spatial learning and memory ability of the mice. The method breaks through the limitation of traditional single-target treatment, multi-dimensional pathological intervention is achieved, the stem cells are rich in source and high in safety, and a new strategy is provided for treatment of the Alzheimer's disease.

The invention belongs to the technical field of biology, and particularly discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and the application provided by the invention realizes overexpression of neurogenesis promoting transcription factors and knock-down of induced hindering factors. The overexpression of neurogenesis promoting transcription factors and the knock-down of induced hinders are expected to become an effective method for improving the transdifferentiation efficiency and generating more new neurons, so that the method can be widely applied to the treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases, central nervous system traumatic diseases and the like.

The invention discloses a traditional Chinese medicine active ingredient composition for treating cerebral infarction and application thereof, and relates to the technical field of traditional Chinese medicines. By optimizing the dosage ratio of the active ingredient compound (calycosin-7-glucoside, formononetin and astragaloside), it is proved that the compound remarkably relieves neurological impairment, reduces the cerebral infarction area, promotes neurogenesis after cerebral infarction and can effectively improve cerebral infarction prognosis, and the effect is equivalent to that of a clinical proved recipe 'Yang-tonifying and five-returning decoction'. The active ingredient composition obtained by the invention has the advantages of clear ingredients, definite mechanism and controllable quality, the safety of clinical medication is improved on the basis of ensuring the curative effect, the hidden danger of adverse reaction is reduced, and a modern compound traditional Chinese medicine which is compatible with active ingredients in a modern dosage form is favorably prepared.

This invention provides a pH-responsive immunomodulatory microneedle patch, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention incorporates Zif-8 nanoparticles loaded with ChABC into GelMA hydrogel to prepare a pH-responsive immunomodulatory microneedle patch (Z@C-MN). As the patch gradually degrades, the system can continuously release Zn in a pH-responsive manner. 2+ Z@C-MN, along with ChABC, promotes in situ repair of cerebral fibrosis (SCI) after injury. Z@C-MN induces macrophage polarization towards a pro-regenerative phenotype, thereby downregulating the inflammatory response, increasing neurite length, and promoting the differentiation of neural stem cells into neurons. In vivo, Z@C-MN reduced the inflammatory microenvironment after injury and promoted angiogenesis in a rat SCI model. Furthermore, it activated axonal regeneration by inhibiting scar tissue formation and regulating CD4+. + T cell transformation supports neurogenesis.

The present invention discloses a bioactive scaffold for slowly releasing Apt19S to recruit endogenous stem cells and guide the straight regeneration of central nervous system axons and its application. The bioactive scaffold is composed of acellular optic nerve (DON) and aptamer Apt19S, and its preparation method comprises the following steps: 1. preparing a DON scaffold. 2. activating the carboxyl group on the surface of the DON scaffold. 3. The DON scaffold is combined with amino-modified Apt19S through an amidation reaction to obtain the DON‑Apt19S scaffold (abbreviated as DON‑A). This bioactive scaffold can continuously release Apt19S, recruit ALPL-positive endogenous neural stem cells and mesenchymal cells, guide the straight regeneration of central nervous system axons, and provide a microenvironment for neurogenesis and angiogenesis for in situ spinal cord repair. The bioactive scaffold has important transformation prospects and application value in the repair of central nervous system injuries.

The present application relates to a composition using an endothelin B receptor agonist, such as Sovastatin (N-succinyl-[Glu9, Ala11, 15] endothelin 1, IRL-1620), for promoting cell proliferation and protecting the original neuroepithelium of cochlear and vestibular cells located within the ear sac. The pharmaceutical composition is systemically administered by means of tympanic membrane puncture, cochleostomy or intravenous or intramuscular injection. A pharmaceutical composition for the treatment of sensorineural hearing loss and vestibular disorders caused by inner ear cell degeneration, the pharmaceutical composition comprising a compound of an endothelin analogue, the use being treated by the neuroprotection and neurogenesis mechanism of cochlear vestibular hair cells and synapses.

The present disclosure relates to injectable, aligneable and electroconductive hydrogel-carbon nanodots nanocomposite materials specifically designed to elicit key cellular functions relevant to in vitro, in vivo and clinical applications, such as neurogenic differentiation of eukaryotic stem cells and their electrophysiological maturation. The nanocomposites uniquely provide distinctive benefits attractive for both pre-clinical and clinical research, such as the potential to use various medically approved hydrogels, the ability to direct neurogenesis without exogenous factors, the capacity to support robust and directional axonal growth while eliciting the functional maturation of neurons through enhanced firing and a more active network activity, the potential for the in vitro and vivo assembly of 3D constructs of variable geometries to create specific architectures and / or follow specific anatomical trajectories, the facile integration of supplemental functions (e.g. drug release), ease of manufacturing and storage.

Cannabinoids are increasingly found to have beneficial effects on the human body, even without the intoxicating effects from THC. Herein we describe a cannabinoid composition of mixed cannabinoids and terpenes. The described cannabinoid composition can be used for improvement of sleep quality, for pain management, and for stimulation of neurogenesis. The typical cannabinoid composition is 90.0% by mass cannabidiol, 4.0% by mass cannabigerol, 2.0% by mass cannabichromene, 2.0% by mass cannabinol, 1.5% by mass beta caryophyllene, and 0.5% by mass myrcene.

The present disclosure relates to the use of compounds of formula (I), compounds of formula (II), and related analogs for enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex), and to methods of enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex). And other methods and uses related thereto.

The present invention discloses a scaffold-gel composite central nervous system repair material for specifically attracting and incubating endogenous neural stem cells and its application. The composite central nervous system repair material is composed of a decellularized optic nerve scaffold, a decellularized spinal cord hydrogel, neurotrophic factors, and the aptamer Apt19S. The above-mentioned scaffold can continuously release Apt19S and neurotrophic factors, recruit a large number of endogenous stem cells, and provide a neurogenesis microenvironment and physical support performance support for in situ spinal cord repair. The composite central nervous system repair material can be transplanted into the spinal cord injury site to repair spinal cord injury, and can also be transplanted into the optic nerve or brain injury site to repair central nervous system injury.

The present disclosure generally relates to novel chimeric antigen receptors ("CARs"), modified regulatory T cells ("Tregs") expressing such CARs and / or Tregs which are engineered to express neurodegenerative disease modifying molecules. More specifically the disclosure provides chimeric antigen receptors (CARs) which comprise a CD44 costimulatory domain or CD44 intracellular domain placed between a transmembrane region and a cytoplasmic CD3zeta domain. The present disclosure more specifically the invention provides immune cells, e.g., Tregs which comprise such CD44 comprising CARs which promote antigen-specific, improved Treg efficacy. CARs comprising the CD44 costimulatory domain or CD44 intracellular domain are shown to promote robust cytokine production by Tregs upon encountering aggregated antigen and surprisingly such CD44 based CARs trigger cytokine at different amounts and ratios than otherwise equivalent CD28 based CARs. Also, the disclosure provides therapeutic methods comprising the administration of immune cells for the treatment of neurogenerative diseases such as Alzheimer's disease.

The invention discloses a pharmaceutical composition for promoting neuron neogenesis and a method for promoting neuron neogenesis by using a gastrodia elata extract or an adenosine analogue. The gastrodia elata extract comprises gastrodin, gastrodigenin, a parishins compound, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde (4-hydroxybenzaldehyde). The invention also discloses a method for promoting neuron neogenesis by using the gastrodia elata extract or the adenosine analogue. The gastrodia elata extract provided by the invention has aging-retarding activity on nerve cells and can induce mouse hippocampal neuronal neogenesis.

A system and method for dual-task neurological therapy using a combination of primary and secondary tasks to facilitate neurogenesis and neuroplasticity in targeted regions of the brain using computer-enhanced dual-task analysis and treatment. The system and method involve having a subject engage in primary and secondary tasks at levels of intensity or stress associated with increased neurogenesis and neuroplasticity. In some embodiments, novel secondary tasks are selected to vary the tasks to help with neurogenesis and neuroplasticity, novel content for the secondary tasks are generated by a generative AI model, adjustments are made to the tasks during performance using a feedback mechanism to adjust for the abilities and performance of the patient, and empathetic feedback is generated by a generative AI model and provided to the patient during performance of tasks.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.